Your session is about to expire
← Back to Search
Quadratus Lumborum vs Erector Spinae Blocks for Postoperative Hip Surgery Pain
Study Summary
This trial will compare the efficacy of two types of blocks - Quadratus Lumborum (QL) and Erector Spinae (ESP) - used in conjunction with a continuous lumbar plexus block (LPB) for postoperative analgesia in children and adolescents undergoing unilateral hip surgical procedures.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been treated with opioids in the last 2 months.I am having surgery to correct my hip, including adjustments or hip replacement.I did not receive a lumbar plexus catheter as initially planned.I have a history of chronic pain.I am having surgery for hip dysplasia and my health is relatively good.You have severe developmental delays.I am between 15 and 30 years old.I have a known blood clotting disorder.You have a very high body mass index (BMI).
- Group 1: Erector spinae supplemental block
- Group 2: Quadratus lumborum supplemental block
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you discuss the security profile of Ropivacaine?
"Reacting to the extensive clinical data, our team at Power assigned Ropivacaine a rating of 3 on safety scale. This is due to its Phase 4 status, which indicates FDA approval."
How many individuals have enrolled in this research project thus far?
"Affirmative. Evidence on clinicaltrials.gov clarifies that this experiment is currently searching for participants, which was first published on December 1st 2020 and has most recently been updated on September 8th 2022. A total of 156 patients are required from lone medical centre."
What medical treatments is Ropivacaine typically utilized for?
"Ropivacaine is a common anesthetic used to relieve pain in surgical procedures, childbirth and postoperative care."
Are there still opportunities for enrolment in this experiment?
"According to clinicaltrials.gov, the enrolment process for this medical trial is ongoing; it was initiated on December 1st 2020 and edited lastly on September 8th 2022."
Is there an age restriction for participants of this medical experiment?
"Those wishing to enter this trial must be aged 15-30. Simultaneously, there are 93 clinical trials for those under 18 and 439 studies targeting people over 65 years of age."
For whom is this research endeavor open?
"Participants must be between 15 and 30 years of age, present with postoperative pain, to qualify for this 156-person clinical trial."
Share this study with friends
Copy Link
Messenger